A Phase 2 interventional study of Saroglitazar in Liver Transplant; Complications and NAFLD, sponsored by Zydus Therapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-24.
Sponsored by Zydus Therapeutics Inc. (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 365th largest by enrollment of the 460 interventional ones that give a count, is one of 62 that started in 2019, is one of 192 in phase 2, and was the 252nd registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 62 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
This study is registered under Zydus Therapeutics Inc., one of the names counted as Zydus Lifesciences Limited. Under that name alone:
Zydus Therapeutics Inc. is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.
Zydus Lifesciences Limited has 7 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2A, single center, open-label, single-arm, 24-week study to evaluate the safety, tolerability and efficacy of Saroglitazar Magnesium 4 mg in liver transplant recipients with NAFLD.
This is a phase 2A, single center, open-label, single-arm, 24-week study to evaluate the safety, tolerability and efficacy of Saroglitazar Magnesium 4 mg in liver transplant recipients with NAFLD.
The study will be conducted over a period of up to 33 weeks and will include 5 weeks screening, a 24 week treatment period and 4 week follow-up period. The primary end point of the study is to assess the safety of Saroglitazar Magnesium 4 mg in liver transplant recipients with NAFLD over 24 weeks of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Graft cirrhosis as defined by:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Saroglitazar Magnesium tablet once daily in the morning 60 minutes before breakfast
Drug: Saroglitazar
Saroglitazar magnesium 4 mg tablet once daily (OD) in the morning 60 minutes before breakfast without food
Also known as: Not any
Number of Participants With Adverse Events Assessed by CTCAE
Safety measured by adverse events, vital signs, physical exams, body weight, electrocardiograms (ECGs) and lab results (including hematology, chemistry and urinalysis)
Time frame: 24 weeks
Hepatic Fat
Changes in hepatic fat as determined by MRI-PDFF from baseline to end-of-treatment (EOT)
Time frame: Baseline and week 24
Liver Stiffness
Changes in Liver stiffness as determined by MRE from baseline to end-of-treatment (EOT) Liver stiffness is a measure of a mechanical property of tissue (stiffness). This can be measured non-invasively by MR elastography, a technique that involves applying an external vibration to the abdomen and measuring the progression of shear waves through the underlying liver using MRI.
Time frame: Baseline and Week 24
Frequently Sampled Intravenous Glucose Tolerance Test (Insulin Resistance Marker)
Changes in frequently sampled intravenous glucose tolerance test (FSIVGTT) from baseline to EOT
Time frame: Baseline and Week 24
Glycosylated Hemoglobin (Insulin Resistance Marker)
Changes in glycosylated hemoglobin (HbA1c) from baseline to EOT
Time frame: Baseline and Week 24
Fructosamine (Insulin Resistance Marker)
Changes in fructosamine from baseline to EOT
Time frame: Baseline and Week 24
Serum Liver Enzymes
Changes in serum liver enzymes from baseline to EOT
Time frame: Baseline and Week 24
Serum Liver Enzymes; Bilirubin
Changes in bilirubin from baseline to EOT
Time frame: Baseline and Week 24
Serum Lipids
Changes in serum lipids from baseline to EOT
Time frame: Baseline and Week 24
Small Dense Low-density Lipoprotein (Atherogenic Lipoprotein)
Changes in small dense low-density lipoprotein (sdLDL) from baseline to EOT
Time frame: Baseline and Week 24
LDL Size (Atherogenic Lipoprotein)
Changes in LDL size from baseline to EOT
Time frame: Baseline and Week 24
LDL Concentration (Atherogenic Lipoprotein)
Changes in LDL concentration from baseline to EOT
Time frame: Baseline and Week 24
Very Low-density Lipoprotein (Atherogenic Lipoprotein)
Changes in subtypes of very low-density lipoprotein (VLDL) from baseline to EOT
Time frame: Baseline and Week 24
Very Low-density Lipoprotein Chylomicron Triglyceride (Atherogenic Lipoprotein)
Changes in VLDL chylomicron triglyceride from baseline to EOT
Time frame: Baseline and Week 24
High-density Lipoprotein (Atherogenic Lipoprotein)
Changes in high-density lipoprotein (HDL) from baseline to EOT
Time frame: Baseline and Week 24
Change in Metabolic Flexibility; Time to Peak RQ
Metabolic flexibility was measured via a whole room calorimeter (i.e. respiration chamber). The CO2 production and O2 consumption were recorded every minute for a total of 18 hours while study participants were in the respiration chamber on baseline and Week 24. Metabolic flexibility was quantified by measuring whole-body CO2 production relative to O2 consumption or respiratory quotient (RQ). The RQ oscillates between 0.7 and 1.0, which is indicative of either predominantly fatty acid or carbohydrate oxidation, respectively. The time to maximal carbohydrate consumption is measured by the time it takes to reach peak RQ after a standardized meal, whereas maximal carbohydrate consumption is measured at the peak of RQ vs. time curve. Next, the transition from maximal carbohydrate consumption to maximal fatty acid consumption is measured from peak RQ to lowest RQ. Finally, fasting biofuel utilization is measured in the fasting state and represents predominantly fatty acid oxidation.
Time frame: Baseline and Week 24
Quality of Life (SF-36 Health Survey)
Change in Quality of life score from baseline to EOT The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as the worst health status
Time frame: Baseline and Week 24
Peak Plasma Concentration [Cmax]
Pharmacokinetics of Saroglitazar following first and last dose.
Time frame: PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Time to Reach Peak Plasma Concentration [Tmax]
Pharmacokinetics of Saroglitazar following first and last dose
Time frame: PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Area Under Plasma Concentration vs. Time Curve Till the Last Time Point [AUC0-t]
Pharmacokinetics of Saroglitazar
Time frame: PK Sampling time points: Day 1 visit at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Area Under Plasma Concentration vs. Time Curve Extrapolated to the Infinity [AUC0-∞]
Pharmacokinetics of Saroglitazar
Time frame: PK Sampling time points: Day 1 visit at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Area Under Plasma Concentration vs. Time Curve in a 24 h Dosing Interval [AUCtau]
Pharmacokinetics of Saroglitazar
Time frame: PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Elimination Rate Constant [λz]
Pharmacokinetics of Saroglitazar
Time frame: PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Elimination Half-life [t1/2]
Pharmacokinetics of Saroglitazar
Time frame: PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Apparent Volume of Distribution [Vd/F]
Pharmacokinetics of Saroglitazar
Time frame: PK Sampling time points: Day 1 (Baseline) and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Apparent Clearance [CL/F]
Pharmacokinetics of Saroglitazar
Time frame: PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Minimal or Trough Plasma Concentration [Cmin]
Pharmacokinetics of Saroglitazar
Time frame: PK Sampling time points: Week 24 visit at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Accumulation Index Calculated as a Ratio of AUCtau (Last Dose)/AUCtau (First Dose)
Pharmacokinetics of Saroglitazar
Time frame: PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Fluctuation Index
Fluctuation index is the peak trough fluctuation within complete dosing interval at steady state, calculated as PTF (%) = (\[Cmax - Cmin\]/Cav ) multiplied by 100
Time frame: PK Sampling time points: Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
| Milestone | Saroglitazar Magnesium 4 mg |
|---|---|
| Started | 20 |
| Completed | 15 |
| Not completed | 5 |
Safety measured by adverse events, vital signs, physical exams, body weight, electrocardiograms (ECGs) and lab results (including hematology, chemistry and urinalysis)
| Participants | Saroglitazar Magnesium 4 mg |
|---|---|
| Number of Participants With Adverse Events Assessed by CTCAE | 12 |
Changes in hepatic fat as determined by MRI-PDFF from baseline to end-of-treatment (EOT)
| percentage of hepatic fat | Saroglitazar Magnesium 4 mg |
|---|---|
| Hepatic Fat | -3.17 ± 5.82 |
Changes in Liver stiffness as determined by MRE from baseline to end-of-treatment (EOT) Liver stiffness is a measure of a mechanical property of tissue (stiffness). This can be measured non-invasively by MR elastography, a technique that involves applying an external vibration to the abdomen and measuring the progression of shear waves through the underlying liver using MRI.
| kPa | Saroglitazar Magnesium 4 mg |
|---|---|
| Liver Stiffness | 0.01 ± 0.34 |
Changes in frequently sampled intravenous glucose tolerance test (FSIVGTT) from baseline to EOT
| mg/dL | Saroglitazar Magnesium 4 mg |
|---|---|
| Frequently Sampled Intravenous Glucose Tolerance Test (Insulin Resistance Marker) | -22.68 ± 29.99 |
Changes in glycosylated hemoglobin (HbA1c) from baseline to EOT
| percentage of glycosylated hemoglobin | Saroglitazar Magnesium 4 mg |
|---|---|
| Glycosylated Hemoglobin (Insulin Resistance Marker) | -0.11 ± 0.57 |
Changes in fructosamine from baseline to EOT
| µmol/L | Saroglitazar Magnesium 4 mg |
|---|---|
| Fructosamine (Insulin Resistance Marker) | -10.90 ± 28.13 |
Changes in serum liver enzymes from baseline to EOT
| U/L | Saroglitazar Magnesium 4 mg |
|---|---|
| Change in ALT | -9.10 ± 23.23 |
| Change in AST | 3.90 ± 17.56 |
| Change in ALP | -42.80 ± 22.07 |
Changes in bilirubin from baseline to EOT
| mg/dL | Saroglitazar Magnesium 4 mg |
|---|---|
| Serum Liver Enzymes; Bilirubin | -0.08 ± 0.16 |
Changes in serum lipids from baseline to EOT
| mg/dL | Saroglitazar Magnesium 4 mg |
|---|---|
| Change in Total Cholesterol | -5.50 ± 20.74 |
| Change in Triglycerides | -43.20 ± 47.92 |
| Change in Non-HDL-C | -6.20 ± 17.31 |
| Change in HDL-C | 0.20 ± 10.27 |
| Change in HDL-C Subclass 2 | -5.30 ± 9.39 |
| Change in HDL-C Subclass 3 | 5.10 ± 5.75 |
| Change in LDL-C | 2.90 ± 19.40 |
| Change in VLDL-C | -8.50 ± 9.49 |
| Change in VLDL concentration | -6.60 ± 13.63 |
| Change in Small dense LDL-C | -4.29 ± 5.17 |
Changes in small dense low-density lipoprotein (sdLDL) from baseline to EOT
| nmol/L | Saroglitazar Magnesium 4 mg |
|---|---|
| Small Dense Low-density Lipoprotein (Atherogenic Lipoprotein) | 51.40 ± 248.45 |
Changes in LDL size from baseline to EOT
| nm | Saroglitazar Magnesium 4 mg |
|---|---|
| LDL Size (Atherogenic Lipoprotein) | 0.17 ± 0.61 |
Changes in LDL concentration from baseline to EOT
| nmol/L | Saroglitazar Magnesium 4 mg |
|---|---|
| LDL Concentration (Atherogenic Lipoprotein) | 21.70 ± 155.44 |
Changes in subtypes of very low-density lipoprotein (VLDL) from baseline to EOT
| nmol/L | Saroglitazar Magnesium 4 mg |
|---|---|
| Change in VLDL chylomicron particles | -20.22 ± 22.92 |
| Change in Large VLDL chylomicron particles | -2.20 ± 2.19 |
| Change in Medium VLDL particles | -13.24 ± 19.47 |
| Change in Small VLDL particles | -4.79 ± 14.53 |
Changes in VLDL chylomicron triglyceride from baseline to EOT
| mg/dL | Saroglitazar Magnesium 4 mg |
|---|---|
| Very Low-density Lipoprotein Chylomicron Triglyceride (Atherogenic Lipoprotein) | -40.70 ± 39.77 |
Changes in high-density lipoprotein (HDL) from baseline to EOT
| µmol/L | Saroglitazar Magnesium 4 mg |
|---|---|
| High-density Lipoprotein (Atherogenic Lipoprotein) | 1.82 ± 4.67 |
Metabolic flexibility was measured via a whole room calorimeter (i.e. respiration chamber). The CO2 production and O2 consumption were recorded every minute for a total of 18 hours while study participants were in the respiration chamber on baseline and Week 24. Metabolic flexibility was quantified by measuring whole-body CO2 production relative to O2 consumption or respiratory quotient (RQ). The RQ oscillates between 0.7 and 1.0, which is indicative of either predominantly fatty acid or carbohydrate oxidation, respectively. The time to maximal carbohydrate consumption is measured by the time it takes to reach peak RQ after a standardized meal, whereas maximal carbohydrate consumption is measured at the peak of RQ vs. time curve. Next, the transition from maximal carbohydrate consumption to maximal fatty acid consumption is measured from peak RQ to lowest RQ. Finally, fasting biofuel utilization is measured in the fasting state and represents predominantly fatty acid oxidation.
| minutes | Saroglitazar Magnesium 4 mg |
|---|---|
| Change in Metabolic Flexibility; Time to Peak RQ | -53.2 ± 78.0 |
Change in Quality of life score from baseline to EOT The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as the worst health status
| score on a scale | Saroglitazar Magnesium 4 mg |
|---|---|
| Physical Component Score | -0.10 ± 7.54 |
| Mental Component Score | 2.63 ± 8.45 |
Pharmacokinetics of Saroglitazar following first and last dose.
| ng/mL | Saroglitazar Magnesium 4 mg |
|---|---|
| first dose (Day 1) | 174.783 ± 53.673 |
| last dose (Week 24) | 115.687 ± 62.680 |
Pharmacokinetics of Saroglitazar following first and last dose
| hours | Saroglitazar Magnesium 4 mg |
|---|---|
| First dose (Day 1) | 1.010 (1.000 to 3.000) |
| Last dose (Week 24) | 2.500 (0.500 to 4.000) |
Pharmacokinetics of Saroglitazar
| (ng/mL)*(hr) | Saroglitazar Magnesium 4 mg |
|---|---|
| Area Under Plasma Concentration vs. Time Curve Till the Last Time Point [AUC0-t] | 689.550 ± 380.816 |
Pharmacokinetics of Saroglitazar
| (ng/mL)*(hr) | Saroglitazar Magnesium 4 mg |
|---|---|
| Area Under Plasma Concentration vs. Time Curve Extrapolated to the Infinity [AUC0-∞] | 698.354 ± 386.372 |
Pharmacokinetics of Saroglitazar
| (ng/mL)*(hr) | Saroglitazar Magnesium 4 mg |
|---|---|
| First dose (Day 1) | 689.504 ± 380.751 |
| Last dose (Week 24) | 805.178 ± 513.106 |
Pharmacokinetics of Saroglitazar
| L/hour | Saroglitazar Magnesium 4 mg |
|---|---|
| First dose (Day 1) | 0.167 ± 0.020 |
| last dose (Week 24) | 0.159 ± 0.024 |
Pharmacokinetics of Saroglitazar
| hour | Saroglitazar Magnesium 4 mg |
|---|---|
| First dose (Day 1) | 4.199 ± 0.479 |
| Last dose (Week 24) | 4.442 ± 0.612 |
Pharmacokinetics of Saroglitazar
| mL | Saroglitazar Magnesium 4 mg |
|---|---|
| First dose | 44028.830 ± 21667.338 |
| Last dose | 40693.327 ± 18934.484 |
Pharmacokinetics of Saroglitazar
| (mL/hr) | Saroglitazar Magnesium 4 mg |
|---|---|
| First dose (Day 1) | 7064.331 ± 3062.337 |
| Last dose (Week 24) | 6658.927 ± 3972.114 |
Pharmacokinetics of Saroglitazar
| ng/mL | Saroglitazar Magnesium 4 mg |
|---|---|
| Minimal or Trough Plasma Concentration [Cmin] | 2.321 ± 1.994 |
Pharmacokinetics of Saroglitazar
| ratio | Saroglitazar Magnesium 4 mg |
|---|---|
| Accumulation Index Calculated as a Ratio of AUCtau (Last Dose)/AUCtau (First Dose) | 1.134 ± 0.203 |
Fluctuation index is the peak trough fluctuation within complete dosing interval at steady state, calculated as PTF (%) = (\[Cmax - Cmin\]/Cav ) multiplied by 100
| percentage | Saroglitazar Magnesium 4 mg |
|---|---|
| Fluctuation Index | 374.965 ± 182.252 |
Collected over 28 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Saroglitazar Magnesium 4 mg | 0/20 (0%) | 2/20 (10%) | 12/20 (60%) |
| Event | Saroglitazar Magnesium 4 mg |
|---|---|
| Mesenteric vein thrombosisGastrointestinal disorders | 1/20 |
| Gastroenteritis viralInfections and infestations | 1/20 |
| Event | Saroglitazar Magnesium 4 mg |
|---|---|
| Glomerular filtration rate decreasedInvestigations | 3/20 |
| Alanine aminotransferase increasedInvestigations | 2/20 |
| Aspartate aminotransferase increasedInvestigations | 2/20 |
| Blood creatinine increasedInvestigations | 2/20 |
| Lipase increasedInvestigations | 2/20 |
| Abdominal painGastrointestinal disorders | 2/20 |
| DiarrhoeaGastrointestinal disorders | 2/20 |
| CellulitisInfections and infestations | 2/20 |
| HypoglycaemiaMetabolism and nutrition disorders | 2/20 |
| Anal incontinenceGastrointestinal disorders | 1/20 |
Safety Population
| Age, Continuous(years) | Saroglitazar Magnesium 4 mg |
|---|---|
| Mean | 58.7 ± 10.96 |
| Sex: Female, Male(Participants) | Saroglitazar Magnesium 4 mg |
|---|---|
| Female | 2 |
| Male | 18 |
| Ethnicity (NIH/OMB)(Participants) | Saroglitazar Magnesium 4 mg |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 19 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Saroglitazar Magnesium 4 mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 16 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Body Mass Index(kg/m2) | Saroglitazar Magnesium 4 mg |
|---|---|
| Mean | 36.8 ± 6.77 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2019 to primary completion in Dec 2021, 33 months.
Results were first posted in Oct 2024, 2 years 10 months after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 33 months is above that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Saroglitazar
Non-alcoholic Fatty Liver Disease →